mRNA vaccines targeting non-tumor-related antigens are potent immune modulators capable of sensitizing tumors to immune checkpoint blockade
fondazionebonadonna.org/en/sars-cov-...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Having a great time at #EACR2025, catching up and continuing doing exciting science with @carloscaldas1960.bsky.social and @caldaslab.bsky.social!

Afami-cel showed durable responses in heavily pretreated patients with sarcoma, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy
fondazionebonadonna.org/en/afamitres...
#fondazionebonadonna #oncology #CancerResearch
@mauriziocallari.bsky.social

I am excited to share the latest publication from the Nguyen, Caldas @carloscaldas1960.bsky.social and Rueda labs @ruedalab.bsky.social. This was a massive effort from a fantastic team and I’m grateful to everyone on the paper for their work on this project! doi.org/10.1016/j.ce...
#bcsm #PDTX

Whole genome sequencing-powered ctDNA sequencing improves detection at baseline and follow-up helping to identify early breast cancer patients at high risk of relapse
www.fondazionemichelangelo.org/news-update/...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

1/n
Fantastic to see this published. Anticipatory genomics demonstration: ctDNA and ML to predict CT progression!
Well done @emmajb001.bsky.social and @mortegaduran.bsky.social! Great collaboration of @caldaslab.bsky.social with @ruedalab.bsky.social!
#DETECT started by @sj-dawson.bsky.social!

Here an overview of our #translational research on samples from the #NAPHER2 trial recently published in #NatComms @natureportfolio.nature.com. We identified #predictive #biomarkers and molecular dynamics in HER2+ER+ #breastcancer receiving chemo-free #targeted #treatment 👇

📢 Our work just published in
@naturecomms.bsky.social @natureportfolio.nature.com!
What is driving #response to #targeted #treatments in HER2+ER+ #breastcancer? How is the tumour ecosystem affected by treatment? Find the answers in our paper 👉 rdcu.be/ecbVR
Key points below 👇

Nivolumab plus ipilimumab show superior progression-free survival versus nivolumab in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
fondazionebonadonna.org/en/nivolumab...
#fondazionebonadonna #oncology #CancerResearch
@mauriziocallari.bsky.social

Listen to episode 19 of The Cancer Researcher Podcast where @carloscaldas1960.bsky.social shares insights into his breast cancer research, the evolution of cancer science & the power of patient-derived xenograft models ahead of his Keynote Talk at EACR 2025.

magazine.eacr.org/insights-fro...

Just finished a Teams meeting with @mauriziocallari.bsky.social and Oscar Rueda discussing Single Nucleus Sequencing generated by @sc10021.bsky.social from 150 #METABRIC breast cancers, in conjunction with all the other multi-omic data. At #EACR2025 update coming...

#MedSky #OncSky #Altmetrics @cosmocollab.bsky.social @oncoalert.bsky.social

Amazing resource for pre-clinical research in triple-negative breast cancer!

We recently announced a dual new release of intOGen and boostDM

Computational analysis of 33,218 tumor genomes to identify cancer genes and driver mutations

➡️ Compendium of Cancer Driver Genes - www.intogen.org

➡️ In Silico Saturation Mutagenesis of Cancer Genes - www.intogen.org/boostdm

A great piece of work, I'm happy to have contributed to during my time in Cambridge! #PDX #breastcancer #drug #response #prediction

Out today in Nature: "The Human Cell Atlas"! In my News and Views, I compare the cell atlas to early naturalists creating an atlas of South America. Researchers mining this cell atlas can now make big discoveries, just as the next naturalists then discovered evolution.
www.nature.com/articles/d41...

I strongly support this